Physician profile
John Webb
NPI 1891762563
$4,516.09
in general payments reported to CMS, 2019-2025
45 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $102 · 2021: $72.42 · 2022: $405 · 2023: $723 · 2024: $1,364 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,047 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,046.75 |
| Education | $141.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $576.73 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Abbvie INC. | $470.76 | 2021-2025 | Botox, Ubrelvy |
| Lilly USA, LLC | $347.09 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Teva Pharmaceuticals USA, INC. | $237.62 | 2022-2025 | Austedo Xr, Austedo Xr |
| Amneal Pharmaceuticals LLC | $216.23 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Alexion Pharmaceuticals, INC. | $199.21 | 2019-2023 | Ultomiris |
| Genzyme Corporation | $186.03 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $181.40 | 2023-2025 | Epidiolex |
| Supernus Pharmaceuticals, INC. | $164.52 | 2019-2020 | |
| Argenx US, INC. | $158.41 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Biohaven Pharmaceutical Holding Company LTD. | $131.93 | 2022 | |
| Ucb, INC. | $124.99 | 2019-2025 | Zilbrysq, Fintepla |
| Ipsen Biopharmaceuticals, INC | $112.96 | 2022-2025 | Dysport |
| Pfizer INC. | $108.07 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $94.76 | 2019-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $91.46 | 2024-2025 | Vyepti |
| Allergan, INC. | $87.51 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.81 | 2023-2024 | Gammagard, Hyqvia |
| Tg Therapeutics, INC. | $78.65 | 2024-2025 | |
| Csl Behring | $78.16 | 2023-2024 | Hizentra, Privigen |
| Vanda Pharmaceuticals INC. | $68.95 | 2024-2025 | Ponvory |
| Sunovion Pharmaceuticals INC. | $63.18 | 2019-2022 | |
| Kyowa Kirin, INC. | $58.03 | 2020-2024 | Nourianz |
| Amgen INC. | $50.93 | 2024-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $48.42 | 2024-2025 | Nuplazid |
| Celltrion USA INC. | $46.48 | 2024 | Zymfentra |
| Emd Serono, INC. | $39.93 | 2019-2025 | |
| Abbott Laboratories | $38.28 | 2023-2024 | Infinity, Amplatzer Talisman |
| Eisai INC. | $37.92 | 2019 | |
| Merz Pharmaceuticals, LLC | $37.61 | 2024 | Xeomin |
| Astrazeneca Pharmaceuticals LP | $31.57 | 2024 | Wainua |
| Celgene Corporation | $26.95 | 2022-2025 | Zeposia |
| Upsher-Smith Laboratories LLC | $25.32 | 2019 | |
| Ge Healthcare | $20.65 | 2019 | |
| Acorda Therapeutics, INC | $20.49 | 2019 | |
| Alnylam Pharmaceuticals INC. | $20.27 | 2024 | Onpattro |
| Neurelis, INC. | $19.38 | 2025 | Valtoco |
| Genentech USA, INC. | $19.31 | 2025 | Ocrevus Zunovo |
| Merz North America, INC. | $19.31 | 2019 | |
| Cycle Pharmaceuticals INC | $18.90 | 2024 | Tascenso Odt |
| Janssen Biotech, INC. | $17.66 | 2025 | |
| Corium, LLC | $17.21 | 2023 | Adlarity |
| Promius Pharma LLC | $16.50 | 2019 | |
| Hospira, INC. | $15.55 | 2024 | |
| Tanabe Pharma America, INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.